Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M

2 days ago 3

Maham Fatima

Sun, May 17, 2026 astatine 11:50 PM CDT 2 min read

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is 1 of the best NASDAQ stocks nether $5 to bargain close now. On May 7, Rocket Pharmaceuticals reported a Q1 2026 nett nonaccomplishment of $47.6 cardinal ($0.42 per share). Driven by a caller realignment and little headcount, R&D expenses fell to $31.5 million, and G&A expenses dropped to $17.1 million. The institution held $144.4 cardinal successful currency astatine quarter-end, which jumps to $322.6 cardinal connected a pro forma ground pursuing the $180 cardinal merchantability of its Priority Review Voucher, extending its operational runway into Q2 2028.

The fiscal runway was boosted by the FDA’s accelerated support of KRESLADI for pediatric patients with terrible leukocyte adhesion deficiency-I (LAD-I). This regulatory milestone granted Rocket a Rare Pediatric Disease Priority Review Voucher, which the institution subsequently monetized for $180 cardinal successful non-dilutive proceeds.

Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M

Dragon Images/Shutterstock.com

In its objective pipeline, Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) reinitiated dosing successful the pivotal Phase 2 proceedings of RP-A501 for Danon illness nether a modified protocol, with a programme update targeted for the 2nd fractional of 2026. The institution is besides aligning with the FDA connected a Phase 2 proceedings plan for RP-A601 successful arrhythmogenic cardiomyopathy, and expects first-patient dosing for its Phase 1 BAG3-dilated cardiomyopathy survey successful mid-2026.

Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) is simply a biotechnology institution focused connected familial therapies for uncommon disorders. Its pipeline includes lentiviral and AAV-based programs targeting immunologic and cardiovascular diseases.

While we admit the imaginable of RCKT arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article